Overview
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
Status:
Completed
Completed
Trial end date:
2010-11-04
2010-11-04
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Metformin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:- Muslim men and women with type 2 diabetes
- Participants who intend to fast during the month of Ramadan
- Participants who have been on a stable dose of sulfonylurea for at least three months
Exclusion Criteria:
- Participants with type 1 diabetes mellitus
- Pregnant or breast feeding women
- Participants with hypersensitivity or contraindication to dipeptidyl peptidase (DPP-4)
treatment
- Participants on insulin
- Participants on any class of oral diabetic therapy other than sulfonylurea or
metformin